Bunina T L, Khondkarian O A, Korshunova T S, Larskiĭ E G, Fuks B B
Zh Nevropatol Psikhiatr Im S S Korsakova. 1976;76(2):166-74.
In the treatment of 31 patients with lateral amyotrophical sclerosis the authors used the preparation ENKAD containing a complex of mono- and oligoribonucleotides. In 6 cases there was aggravation of the condition while in 18 of the observed cases--improvement. In 7 patients the condition was not altered. The treatment was convened under biochemical control (the assessment of the uric acid in the blood serum and urine and the excretion of oxypurine in the urine). It was possible to depict definite clinicobiochemical correlations. The conclusion is made that ENKAD can be used in the early stages of the disease and mainly in focal segmentary-nuclear lesions. The preparation is contraindicated in generalization of the process and in impetuous development of the disorder.
在治疗31例侧索肌萎缩硬化症患者时，作者使用了含有单核苷酸和寡核苷酸复合物的恩卡德制剂。6例病情加重，18例观察病例病情改善。7例患者病情未改变。治疗在生化控制下进行（评估血清和尿液中的尿酸以及尿液中氧嘌呤的排泄）。可以描绘出明确的临床生化相关性。得出的结论是，恩卡德可用于疾病的早期阶段，主要用于局灶性节段性核损害。该制剂在病情扩散和疾病迅速发展时禁用。
